Positive Outlook for Day One Biopharmaceuticals’ Ojemda: A Promising First-Line Treatment for Pediatric Glioma

Analyst Soumit Roy of JonesTrading maintained a Buy rating on Day One Biopharmaceuticals (DAWN – Research Report), retaining the price target of $26.00.

Soumit Roy has given his Buy rating due to a combination of factors that highlight the potential of Day One Biopharmaceuticals’ Ojemda. The drug’s ability to facilitate growth recovery in children under 12 years old, even after discontinuation, addresses a significant concern regarding its long-term adoption. Physicians at ASCO expressed a willingness to use Ojemda as a first-line treatment due to its convenient once-weekly dosing in an outpatient setting, contrasting with chemotherapy’s more demanding requirements.
Additionally, Ojemda’s side effect profile is more favorable compared to other MEK inhibitors, with less severe rashes that resolve within a few months. The drug’s reversible effect on growth suppression simplifies decision-making for parents, making it a preferable option over chemotherapy. Furthermore, the continued durability of response post-discontinuation and the absence of severe adverse events like intratumoral hemolysis contribute to the positive outlook for Ojemda’s use in treating pediatric glioma patients.

Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Elicio Therapeutics, and Chimerix. According to TipRanks, Roy has an average return of -25.7% and a 18.07% success rate on recommended stocks.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $36.00 price target.